Literature DB >> 16511916

Quinacrine but not chloroquine inhibits PMA induced upregulation of matrix metalloproteinases in leukocytes: quinacrine acts at the transcriptional level through a PLA2-independent mechanism.

Karl M Stuhlmeier1, Christine Pollaschek.   

Abstract

OBJECTIVE: Macrophages play an important role in rheumatoid arthritis (RA). RA is a disease characterized by the successive accumulation of leukocytes resulting in subsequent destruction of affected joints. Activation of matrix metalloproteinases (MMP) is essential for many physiological as well as many pathological events owing to the essential role of MMP in cell migration. We analyzed the effectiveness of quinacrine as an inhibitor of MMP activation in leukocytes and investigated the mode of action.
METHODS: Leukocytes were isolated and treated with quinacrine with or without phorbol myristic acetate (PMA). ELISA and RT-PCR were used to monitor production of MMP-1, MMP-2, MMP-3, and MMP-8 at the mRNA and protein level.
RESULTS: Quinacrine suppressed PMA induced MMP-1 release in mononuclear cells (MNC) in a dose- and time-dependent manner. RT-PCR showed that quinacrine downregulated induced as well as noninduced steady-state mRNA levels of MMP-1, MMP-2, and MMP-8, but had no effect on MMP-3. The observed inhibition was not due to effects of quinacrine on phospholipase A2 (PLA2) activity. Adding exogenous arachidonic acid to reconstitute the blocked PLA2 signaling pathways did not result in restoration of PMA induced mRNA transcription.
CONCLUSION: Inhibition of MMP by quinacrine might, in part, account for its reported immunosuppressive action. Synthesizing more potent derivatives of quinacrine may be a means of suppressing undesired MMP activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511916

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Effects of mannose-binding lectin on pulmonary gene expression and innate immune inflammatory response to ozone.

Authors:  Jonathan M Ciencewicki; Kirsten C Verhein; Kevin Gerrish; Zachary R McCaw; Jianying Li; Pierre R Bushel; Steven R Kleeberger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-04-22       Impact factor: 5.464

Review 2.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

Authors:  Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

3.  Bioanalytical Screening of Riboflavin Antagonists for Targeted Drug Delivery - A Thermodynamic and Kinetic Study.

Authors:  Anna Plantinga; Amanda Witte; Ming-Hsin Li; Andrew Harmon; Seok Ki Choi; Mark M Banaszak Holl; Bradford G Orr; James R Baker; Kumar Sinniah
Journal:  ACS Med Chem Lett       Date:  2011-05-12       Impact factor: 4.345

4.  Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.

Authors:  Nickolay Neznanov; Anton V Gorbachev; Lubov Neznanova; Andrei P Komarov; Katerina V Gurova; Alexander V Gasparian; Amiya K Banerjee; Alexandru Almasan; Robert L Fairchild; Andrei V Gudkov
Journal:  Cell Cycle       Date:  2009-12-25       Impact factor: 4.534

Review 5.  Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis.

Authors:  Carolyn M Dancevic; Daniel R McCulloch
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

Review 6.  New concepts in antimalarial use and mode of action in dermatology.

Authors:  Sunil Kalia; Jan P Dutz
Journal:  Dermatol Ther       Date:  2007 Jul-Aug       Impact factor: 2.851

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.